Effectiveness of Vildagliptin in Clinical Practice

Pooled Analysis of Three Korean Observational Studies (the VICTORY Study)

Sunghwan Suh, Sun Ok Song, Jae Hyeon Kim, Hyungjin Cho, Woo Je Lee, byungwan lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The present observational study aimed to evaluate the clinical effectiveness of vildagliptin with metformin in Korean patients with type 2 diabetes mellitus (T2DM). Data were pooled from the vildagliptin postmarketing survey (PMS), the vildagliptin/metformin fixed drug combination (DC) PMS, and a retrospective observational study of vildagliptin/metformin (fixed DC or free DC). The effectiveness endpoint was the proportion of patients who achieved a glycemic target (HbA1c) of ≤7.0% at 24 weeks. In total, 4303 patients were included in the analysis; of these, 2087 patients were eligible. The mean patient age was 56.99 ± 11.25 years. Overall, 58.94% patients achieved an HbA1c target of ≤7.0% at 24 weeks. The glycemic target achievement rate was significantly greater in patients with baseline HbA1c < 7.5% versus ≥7.5% (84.64% versus 43.97%), receiving care at the hospital versus clinic (67.95% versus 52.33%), and receiving vildagliptin/metformin fixed DC versus free DC (70.69% versus 55.42%). Multivariate logistic regression analysis indicated that disease duration (P<0.0001), baseline HbA1c (P<0.0001), and DC type (P=0.0103) had significant effects on drug effectiveness. Vildagliptin plus metformin appeared as an effective treatment option for patients with T2DM in clinical practice settings in Korea.

Original languageEnglish
Article number5282343
JournalJournal of Diabetes Research
Volume2017
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Observational Studies
Drug Combinations
Metformin
Type 2 Diabetes Mellitus
vildagliptin
Korea
Retrospective Studies
Logistic Models
Regression Analysis
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{c72012d4fb5548529cf055ecba61dc35,
title = "Effectiveness of Vildagliptin in Clinical Practice: Pooled Analysis of Three Korean Observational Studies (the VICTORY Study)",
abstract = "The present observational study aimed to evaluate the clinical effectiveness of vildagliptin with metformin in Korean patients with type 2 diabetes mellitus (T2DM). Data were pooled from the vildagliptin postmarketing survey (PMS), the vildagliptin/metformin fixed drug combination (DC) PMS, and a retrospective observational study of vildagliptin/metformin (fixed DC or free DC). The effectiveness endpoint was the proportion of patients who achieved a glycemic target (HbA1c) of ≤7.0{\%} at 24 weeks. In total, 4303 patients were included in the analysis; of these, 2087 patients were eligible. The mean patient age was 56.99 ± 11.25 years. Overall, 58.94{\%} patients achieved an HbA1c target of ≤7.0{\%} at 24 weeks. The glycemic target achievement rate was significantly greater in patients with baseline HbA1c < 7.5{\%} versus ≥7.5{\%} (84.64{\%} versus 43.97{\%}), receiving care at the hospital versus clinic (67.95{\%} versus 52.33{\%}), and receiving vildagliptin/metformin fixed DC versus free DC (70.69{\%} versus 55.42{\%}). Multivariate logistic regression analysis indicated that disease duration (P<0.0001), baseline HbA1c (P<0.0001), and DC type (P=0.0103) had significant effects on drug effectiveness. Vildagliptin plus metformin appeared as an effective treatment option for patients with T2DM in clinical practice settings in Korea.",
author = "Sunghwan Suh and Song, {Sun Ok} and Kim, {Jae Hyeon} and Hyungjin Cho and Lee, {Woo Je} and byungwan lee",
year = "2017",
month = "1",
day = "1",
doi = "10.1155/2017/5282343",
language = "English",
volume = "2017",
journal = "Journal of Diabetes Research",
issn = "2314-6745",
publisher = "Hindawi Publishing Corporation",

}

Effectiveness of Vildagliptin in Clinical Practice : Pooled Analysis of Three Korean Observational Studies (the VICTORY Study). / Suh, Sunghwan; Song, Sun Ok; Kim, Jae Hyeon; Cho, Hyungjin; Lee, Woo Je; lee, byungwan.

In: Journal of Diabetes Research, Vol. 2017, 5282343, 01.01.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effectiveness of Vildagliptin in Clinical Practice

T2 - Pooled Analysis of Three Korean Observational Studies (the VICTORY Study)

AU - Suh, Sunghwan

AU - Song, Sun Ok

AU - Kim, Jae Hyeon

AU - Cho, Hyungjin

AU - Lee, Woo Je

AU - lee, byungwan

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The present observational study aimed to evaluate the clinical effectiveness of vildagliptin with metformin in Korean patients with type 2 diabetes mellitus (T2DM). Data were pooled from the vildagliptin postmarketing survey (PMS), the vildagliptin/metformin fixed drug combination (DC) PMS, and a retrospective observational study of vildagliptin/metformin (fixed DC or free DC). The effectiveness endpoint was the proportion of patients who achieved a glycemic target (HbA1c) of ≤7.0% at 24 weeks. In total, 4303 patients were included in the analysis; of these, 2087 patients were eligible. The mean patient age was 56.99 ± 11.25 years. Overall, 58.94% patients achieved an HbA1c target of ≤7.0% at 24 weeks. The glycemic target achievement rate was significantly greater in patients with baseline HbA1c < 7.5% versus ≥7.5% (84.64% versus 43.97%), receiving care at the hospital versus clinic (67.95% versus 52.33%), and receiving vildagliptin/metformin fixed DC versus free DC (70.69% versus 55.42%). Multivariate logistic regression analysis indicated that disease duration (P<0.0001), baseline HbA1c (P<0.0001), and DC type (P=0.0103) had significant effects on drug effectiveness. Vildagliptin plus metformin appeared as an effective treatment option for patients with T2DM in clinical practice settings in Korea.

AB - The present observational study aimed to evaluate the clinical effectiveness of vildagliptin with metformin in Korean patients with type 2 diabetes mellitus (T2DM). Data were pooled from the vildagliptin postmarketing survey (PMS), the vildagliptin/metformin fixed drug combination (DC) PMS, and a retrospective observational study of vildagliptin/metformin (fixed DC or free DC). The effectiveness endpoint was the proportion of patients who achieved a glycemic target (HbA1c) of ≤7.0% at 24 weeks. In total, 4303 patients were included in the analysis; of these, 2087 patients were eligible. The mean patient age was 56.99 ± 11.25 years. Overall, 58.94% patients achieved an HbA1c target of ≤7.0% at 24 weeks. The glycemic target achievement rate was significantly greater in patients with baseline HbA1c < 7.5% versus ≥7.5% (84.64% versus 43.97%), receiving care at the hospital versus clinic (67.95% versus 52.33%), and receiving vildagliptin/metformin fixed DC versus free DC (70.69% versus 55.42%). Multivariate logistic regression analysis indicated that disease duration (P<0.0001), baseline HbA1c (P<0.0001), and DC type (P=0.0103) had significant effects on drug effectiveness. Vildagliptin plus metformin appeared as an effective treatment option for patients with T2DM in clinical practice settings in Korea.

UR - http://www.scopus.com/inward/record.url?scp=85029159760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029159760&partnerID=8YFLogxK

U2 - 10.1155/2017/5282343

DO - 10.1155/2017/5282343

M3 - Article

VL - 2017

JO - Journal of Diabetes Research

JF - Journal of Diabetes Research

SN - 2314-6745

M1 - 5282343

ER -